포도막염 치료제 시장 규모, 점유율, 성장 분석 : 질환 유형별, 치료 유형별, 원인별, 투여 경로별, 유통 채널별, 적응증별, 지역별 - 산업 예측(2025-2032년)
Uveitis Treatment Market Size, Share, Growth Analysis, By Disease Type, By Treatment Type, By Cause, By Route of Administration, By Distribution Channel, By Indication, By Region - Industry Forecast 2025-2032
상품코드:1633544
리서치사:SkyQuest
발행일:2025년 01월
페이지 정보:영문 239 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 포도막염 치료제 시장 규모는 2023년에 7억 5,800만 달러로 평가되며, 2024년 8억 879만 달러에서 2032년에는 13억 5,878만 달러로 성장하며, 예측 기간(2025-2032년)의 CAGR은 6.7%로 성장할 전망입니다.
안과 시장은 연구개발 활동의 활성화로 인해 강력한 성장세를 보이고 있습니다. 안구 염증, 특히 난치성 후방 포도막염과 중간 포도막염을 대상으로 한 임상시험이 전 세계에서 증가하고 있습니다. 현재 진행 중인 임상 3상 시험에서 미코페놀산 모페틸과 메토트렉세이트와 같은 혁신적인 치료법이 비감염성 포도막염에 대한 표준 코르티코스테로이드 치료의 대안으로 평가되고 있습니다. 또한 광범위한 조사 개발 노력을 통해 생물학적 약물의 개발이 진행되어 안구 염증성 질환에 대한 치료법이 다양해졌습니다. 이러한 발전은 치료 옵션의 다양화를 가져왔을 뿐만 아니라, 이러한 혁신적 치료법에 대한 수요 증가를 촉진하여 안과 영역의 전체 시장 성장을 촉진하고 있습니다.
목차
서론
조사의 목적
조사 범위
정의
조사 방법
정보 조달
2차 데이터와 1차 데이터 방법
시장 규모 예측
시장의 전제조건과 제한
개요
세계 시장 전망
공급과 수요의 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
촉진요인과 기회
억제요인과 과제
Porter의 산업 분석
주요 시장 인사이트
주요 성공 요인
경쟁의 정도
주요 투자 기회
시장 에코시스템
시장의 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
규제 상황
사례 연구
기술의 진보
포도막염 치료제 시장 규모 : 질환 유형별
시장 개요
전부 포도막염
후부 포도막염
중간 포도막염
포도막염
포도막염 치료제 시장 규모 : 치료 유형별
시장 개요
코르티코스테로이드
면역억제제
모노클로널 항체
Cycloplegic Agents
항생제
항바이러스제
항진균
진통제
포도막염 치료제 시장 규모 : 원인별
시장 개요
감염성
비감염성
포도막염 치료제 시장 규모 : 투여 경로별
시장 개요
국소
전신
주사
초자체내
포도막염 치료제 시장 규모 : 유통 채널별
시장 개요
병원 약국
소매 약국
온라인 약국
기타
포도막염 치료제 시장 규모 : 적응증별
시장 개요
전부 포도막염
중간 포도막염
후부 포도막염
포도막염
포도막염 치료제 시장 규모
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽 지역
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카 지역
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채택한 전략
시장의 최근 동향
기업의 시장 점유율 분석(2024년)
주요 기업의 기업 개요
회사 개요
제품 포트폴리오 분석
부문별 점유율 분석
매출의 전년대비 비교(2022-2024년)
주요 기업 개요
AbbVie Inc.(United States)
Novartis AG(Switzerland)
Bausch Health Companies Inc.(Canada)
EyePoint Pharmaceuticals, Inc.(United States)
Santen Pharmaceutical Co., Ltd.(Japan)
Alimera Sciences, Inc.(United States)
Clearside Biomedical, Inc.(United States)
Eyegate Pharmaceuticals, Inc.(United States)
Horizon Therapeutics Plc(Ireland)
Mylan N.V.(United States)
Sun Pharmaceutical Industries Ltd.(India)
Regeneron Pharmaceuticals, Inc.(United States)
Merck & Co., Inc.(United States)
Otsuka Pharmaceutical Co., Ltd.(Japan)
Pfizer Inc.(United States)
Amgen Inc.(United States)
Sanofi(France)
Galapagos NV(Belgium)
Tarsier Pharma Ltd.(Israel)
TopiVert Ltd.(United Kingdom)
결론과 권장사항
KSA
영문 목차
영문목차
Global Uveitis Treatment Market size was valued at USD 758.0 million in 2023 and is poised to grow from USD 808.79 million in 2024 to USD 1358.78 million by 2032, growing at a CAGR of 6.7% during the forecast period (2025-2032).
The ophthalmology market is witnessing a robust expansion fueled by intensified research and development activities. A growing number of clinical trials are underway globally, targeting eye inflammation issues, particularly refractory posterior and intermediate uveitis. Current phase III trials are assessing innovative therapies like mycophenolate mofetil and methotrexate, which are being positioned as alternatives to standard corticosteroid treatments for noninfectious uveitis. Moreover, advancements in the development of biological drugs through extensive R&D efforts have enriched the therapeutic landscape for eye inflammation disorders. This evolution is not only diversifying treatment options but also spurring heightened demand for these innovative therapies, thereby propelling overall market growth in the field of ophthalmology.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Uveitis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Uveitis Treatment Market Segmental Analysis
Global Uveitis Treatment Market is segmented by Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication and region. Based on Disease Type, the market is segmented into Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis and Panuveitis. Based on Treatment Type, the market is segmented into Corticosteroids, Immunosuppressant, Monoclonal Antibodies, Cycloplegic Agents, Antibiotics, Antivirals, Antifungal and Analgesics. Based on Cause, the market is segmented into Infectious and Non-infectious. Based on Route of Administration, the market is segmented into Topical, Systemic, Injectable and Intravitreal. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on Indication, the market is segmented into Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis and Panuveitis. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Uveitis Treatment Market
The global uveitis treatment market is primarily driven by the rising incidence and prevalence of uveitis across the globe, fueled by factors such as autoimmune diseases, infections, and inflammatory conditions. The introduction of innovative treatment options, including biologic therapies, immunosuppressants, and targeted therapies, has greatly enhanced the management of this condition, leading to more effective and specific treatment modalities. Additionally, heightened awareness surrounding uveitis among healthcare professionals and patients has facilitated earlier diagnoses and prompt treatment, further increasing the demand for various uveitis treatment options. These elements collectively contribute to the robust growth of the uveitis treatment market.
Restraints in the Global Uveitis Treatment Market
Global Uveitis Treatment faces significant challenges including limited access to healthcare facilities and specialized care in low-resource settings, contributing to disparities in diagnosis and management across regions. The diversity in underlying causes of uveitis, ranging from infectious to autoimmune and idiopathic origins, complicates standardized treatment protocols. Additionally, varying levels of awareness and education among healthcare providers can lead to mismanagement or delayed treatment. Economic constraints, coupled with the availability of medications, further restrict effective treatment options. Therefore, addressing these barriers necessitates a coordinated global effort to improve access to education, resources, and healthcare infrastructure for uveitis management globally.
Market Trends of the Global Uveitis Treatment Market
The Global Uveitis Treatment market is witnessing significant trends driven by innovation and personalized medicine. There is an accelerated development of targeted therapies, particularly biologics and immunomodulatory drugs, enhancing the management of inflammation in uveitis patients. The adoption of sustained-release drug delivery systems, such as intravitreal implants, is growing, facilitating prolonged drug action and minimizing injection frequency. Furthermore, personalized medicine is gaining traction as genetic and molecular profiling offers tailored treatment strategies. Collaborations between pharmaceutical firms and research institutions are fostering the creation of novel therapies, while the infusion of advanced technologies like AI and telemedicine is revolutionizing patient monitoring and management.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Advancement
Global Uveitis Treatment Market Size by Disease Type & CAGR (2025-2032)
Market Overview
Anterior Uveitis
Posterior Uveitis
Intermediate Uveitis
Panuveitis
Global Uveitis Treatment Market Size by Treatment Type & CAGR (2025-2032)
Market Overview
Corticosteroids
Immunosuppressant
Monoclonal Antibodies
Cycloplegic Agents
Antibiotics
Antivirals
Antifungal
Analgesics
Global Uveitis Treatment Market Size by Cause & CAGR (2025-2032)
Market Overview
Infectious
Non-infectious
Global Uveitis Treatment Market Size by Route of Administration & CAGR (2025-2032)
Market Overview
Topical
Systemic
Injectable
Intravitreal
Global Uveitis Treatment Market Size by Distribution Channel & CAGR (2025-2032)
Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Global Uveitis Treatment Market Size by Indication & CAGR (2025-2032)
Market Overview
Anterior Uveitis
Intermediate Uveitis
Posterior Uveitis
Panuveitis
Global Uveitis Treatment Market Size & CAGR (2025-2032)
North America (Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication)
US
Canada
Europe (Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication)
Brazil
Rest of Latin America
Middle East & Africa (Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication)
